A Rhode Island cardiologist surrendered his medical license November 18 after a federal indictment charged him with a health-care fraud scheme, while two other physicians received reprimands and fines for prescribing violations, the Rhode Island Department of Health announced.
The indictment alleges Finkelstein, as medical director of a cardiovascular testing company, used two firms he owned — Cardiovascular Testing Services PA and Cardiovascular Healthcare Associates PA — to submit false claims to private and public insurers for EKGs and echocardiograms performed on student athletes at school campuses nationwide.
Finkelstein indictment details
Prosecutors allege Finkelstein and co-conspirators marketed tests by preying on fears of sudden cardiac arrest in student athletes. The indictment states Finkelstein was the only ordering provider for the claims but did not conduct clinical examinations to determine whether athletes had symptoms warranting the tests.
Claims fraudulently included false diagnoses to induce payment and falsely stated Finkelstein was the reviewing provider, though he signed off on results within seconds of accessing them.
At least one student-athlete died from complications due to an enlarged heart approximately 24 days after Finkelstein had signed off on the student’s test results as normal, according to the U.S. Department of Justice. No finding of criminal conduct has been made.
Stuart reprimanded for Semaglutide prescribing
Dr. Susan M. Stuart, a board-certified pediatrician licensed since November 1997 who also operates an aesthetics practice including weight-loss management, received a reprimand and must pay a $1,100 administrative fee after a patient complaint over improper Semaglutide prescribing and distribution.
A consent decree signed by Stuart shows the Investigative Committee found she failed to obtain appropriate medical histories, conduct physical examinations, measure vital signs beyond height and weight, coordinate care with patients’ primary care providers, or perform medication reconciliation. Records for two patients with normal BMI readings of 23.5 and 24.4 showed no documented clinical reason for Semaglutide prescriptions other than a desire to lose additional weight.
"patient has sent many referrals" for weight-loss treatment, one chart noted. Another recorded that a patient was given a vial of Semaglutide to give to the complainant when they could not make an appointment.
Stuart acknowledged during a March 25 interview that she did not report Semaglutide prescriptions to patients’ primary care providers and indicated patients often sought treatment after their PCPs were unable to prescribe it or insurance denied coverage. She must complete additional education courses.
Bradley reprimanded for opioid prescribing
Dr. Michael Bradley, a physician licensed since May 2006 and affiliated with Orthopedics Rhode Island, Inc., received a reprimand, a $1,100 administrative fee, and a $1,000 fine after a pharmacist’s complaint alleging unsafe opioid prescribing practices.
Review of eight patients’ records showed Bradley prescribed opioids for postoperative pain for prolonged periods ranging from 20 to 127 months, with a median of 68 months. Doses ranged from 75 to 630 morphine milligram equivalents (MMEs) per day, written for 14-day or shorter courses suggestive of acute pain treatment. Every patient received early refills.
Among the eight patients: naloxone was prescribed to only two; two obtained oxycodone refills while admitted to acute-care hospitals or a skilled nursing facility; two were not seen in-person every six months during prolonged opioid therapy; and two had documented histories of opioid-use disorder and were on buprenorphine before Bradley prescribed opioids.
One patient received benzodiazepines and Adderall for at least 17 months alongside 90 MMEs/day of oxycodone, with no diagnoses supporting those prescriptions by an orthopedic surgeon.
Records lacked evidence of informed consent for controlled substances, including discussions of risks combining opioids with benzodiazepines, stimulants, cannabis, or alcohol. No treatment plans documented objectives for determining success. Prior to the complaint, none of the patients were being weaned from long-term, high-dose opioid therapy, and Bradley did not consider opioid-use disorder or diversion despite risk indicators.
Bradley must complete a board-approved course on controlled substances, comprehensive pain management, and identification and referral for substance-use disorder within six months.